LAMISIL CREAM

Dryness, redness, itching, burning, peeling, rash, stinging, tingling, or other signs of skin irritation that were not present before use of this medicine

ABSOLUTE CONTRAINDICATIONS :

RELATIVE CONTRAINDICATIONS :

Onychomycosis

ADULT DOSE:

Tinea corporis or Tinea cruris- Topical, to the skin and surrounding areas, one or two times a day. Treatment should be continued for at least one week and until there is significant improvement in the clinical signs and symptoms of the disease. Treatment should not be continued beyond four weeks. Tinea pedis, interdigital- Topical, to the skin and surrounding areas, two times a day. Treatment should be continued for at least one week and until there is significant improvement in the clinical signs and symptoms of the disease. Treatment should not be continued beyond four weeks. Tinea pedis, plantar- Topical, to the skin and surrounding areas, two times a day. Treatment should be continued for two weeks. Treatment may be affected by the presence of onychomycosis. Patients with a toenail infection may be less likely to respond favorably to terbinafine therapy. [Tinea versicolor] - Topical, to the skin and surrounding areas, one or two times a day for two weeks. [Cutaneous candidiasis] - Topical, to the skin and surrounding areas, one or two times a day for one or two weeks.

MAXIMUM ADULT DOSE:

PEDIATRIC DOSE:

Tinea corporis or Tinea cruris or Tinea pedis- Infants and children younger than 12 years of age: Safety and efficacy have not been established. Children 12 years of age and older: See Usual adult and adolescent dose. [Tinea versicolor] or [Cutaneous candidiasis] - Safety and efficacy have not been established for these indications.

MAXIMUM PEDIATRIC DOSE:

ELDERLY DOSE:

PREVIOUS

NEXT